Progyny Intrinsic Value Calculation – Barclays Analysts Give Progyny New Coverage Boost
January 7, 2024
☀️Trending News
Barclays Analysts have recently given Progyny ($NASDAQ:PGNY) a boost with their new coverage of the company. Progyny is a leading fertility and family building benefits company that is committed to helping individuals and couples start and grow their families. They provide a range of innovative, personalized programs, services, and products that are designed to assist people in achieving their family-building goals. In addition to their benefits packages, they also offer clinical care and financial support to those who need it.
By providing these resources and services, Progyny seeks to make family planning more accessible and less costly. With the new coverage from Barclays Analysts, Progyny is poised to expand its reach and impact even further.
Stock Price
On Thursday, Barclays analysts gave Progyny a new coverage boost when the stock opened at $36.4 and closed at $35.6, down by 1.6% from its prior closing price of $36.2. In their report, the analysts noted that Progyny is one of the few tech companies that provides fertility benefits to employers’ health plans and praised its ability to leverage analytics and technology to optimize women’s fertility care. They also highlighted the company’s strong growth profile and potential for long-term scalability. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Progyny. More…
| Total Revenues | Net Income | Net Margin |
| 1.03k | 51.98 | 5.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Progyny. More…
| Operations | Investing | Financing |
| 202.67 | -108.28 | -8.83 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Progyny. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 726.51 | 211.12 | 5.38 |
Key Ratios Snapshot
Some of the financial key ratios for Progyny are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 49.4% | 82.2% | 5.0% |
| FCF Margin | ROE | ROA |
| 19.3% | 6.6% | 4.4% |
Analysis – Progyny Intrinsic Value Calculation
At GoodWhale, we recently carried out an analysis to assess the wellbeing of PROGYNY share. Through our proprietary Valuation Line, we determined that the intrinsic value of PROGYNY stock is around $69.2. Currently, the market is trading PROGYNY stock at $35.6, which means that it is currently undervalued by 48.6%. This suggests that PROGYNY share may be a good investment opportunity given its current price. Progyny_New_Coverage_Boost”>More…
Peers
Its competitors are Owlet Inc, ATI Physical Therapy Inc, NantHealth Inc.
– Owlet Inc ($NYSE:OWLT)
Owlet Inc is a privately held company that provides smart baby monitoring products and services. The company was founded in 2013 and is headquartered in Lehi, Utah. Owlet’s product line includes the Owlet Smart Sock, a wearable sensor that monitors a baby’s heart rate and oxygen levels; the Owlet Cam, a Wi-Fi connected camera that streams live video and audio to a smartphone; and the Owlet App, which allows parents to track their baby’s health data. Owlet has raised over $50 million in venture capital funding, and its products are available for purchase online and in select retail stores.
– ATI Physical Therapy Inc ($NYSE:ATIP)
ATI Physical Therapy Inc is a provider of physical therapy and rehabilitation services in the United States. The company operates through a network of over 300 physical therapy clinics in 27 states. ATI Physical Therapy Inc offers a variety of services, including physical therapy, occupational therapy, and speech-language pathology. The company also provides a range of rehabilitation services, such as sports medicine, workers’ compensation, and concussion management.
– NantHealth Inc ($NASDAQ:NH)
NantHealth Inc is a healthcare technology company that provides solutions to improve clinical outcomes and patient experience. The company has a market cap of $37.84 million and a return on equity of 14.38%. NantHealth’s solutions are used by healthcare providers to manage and coordinate care for patients. The company’s products and services include electronic health records, clinical decision support, and patient engagement.
Summary
Progyny Inc. recently received new coverage from Barclays analysts, with the analysts citing Progyny’s strong position in the fertility benefits industry. The analysts noted that Progyny’s membership base, comprehensive services, and focus on improving outcomes would create a strong competitive advantage. They also highlighted Progyny’s strong partnerships with employers and health plans as additional points of strength. Furthermore, the analysts felt that Progyny was well-positioned to benefit from increased demand for its services due to the growing number of women delaying childbearing.
